Literature DB >> 2048826

Mycobacterium avium complex pulmonary disease. Incidence, presentation, and response to therapy in a community setting.

J M Reich1, R E Johnson.   

Abstract

The experience with pulmonary disease caused by Mycobacterium avium complex (MAC-PD) was examined over a 12-yr period in a nonreferral setting. The 29 patients with the disease constituted 30% of all pleuropulmonary mycobacterioses. The mean annual incidence rate was 1/100,000. Sixty-two percent of patients were female, the majority of whom had no discernible preexisting pulmonary disorder to account for their susceptibility. A short- and long-term favorable response to therapy was observed in more than 90% of the 16 patients treated with intent to cure. Suggested as plausible explanations for the favorable response rate compared with previous studies originating in referral settings were: absence of adverse selection as shown by a smaller proportion of patients with far-advanced cavitary disease or with previous treatment failure, and a larger proportion of female patients. A previously unreported pattern of MAC-PD was observed: disease limited to the lingula or middle lobe occurred in 21% of the patients, all female. A rarely identified pattern, primary disease in a 3-yr-old exposed to pet birds, is reported.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2048826     DOI: 10.1164/ajrccm/143.6.1381

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  18 in total

1.  Species identification of Mycobacterium avium complex isolates by a variety of molecular techniques.

Authors:  M L Beggs; R Stevanova; K D Eisenach
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 2.  Management of nontuberculous mycobacterial infection in the elderly.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Golnaz Ebrahimi; Stefano Aliberti; Joseph O Falkinham
Journal:  Eur J Intern Med       Date:  2014-03-29       Impact factor: 4.487

Review 3.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

4.  Subspecies identification and significance of 257 clinical strains of Mycobacterium avium.

Authors:  Quynh T Tran; Xiang Y Han
Journal:  J Clin Microbiol       Date:  2014-02-05       Impact factor: 5.948

5.  Nontuberculous mycobacterial lung infections in Ontario, Canada: clinical and microbiological characteristics.

Authors:  Theodore K Marras; Mauli Mehta; Pamela Chedore; Kevin May; Mohammed Al Houqani; Frances Jamieson
Journal:  Lung       Date:  2010-04-11       Impact factor: 2.584

6.  Clinical and prognostic importance of serotyping Mycobacterium avium-Mycobacterium intracellulare complex isolates in human immunodeficiency virus-negative patients.

Authors:  Ryoji Maekura; Yoshinari Okuda; Atsusi Hirotani; Seigo Kitada; Touru Hiraga; Kenji Yoshimura; Ikuya Yano; Kazuo Kobayashi; Masami Ito
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

7.  Low in vitro production of interferon-gamma and tumor necrosis factor-alpha in HIV-seronegative patients with pulmonary disease caused by nontuberculous mycobacteria.

Authors:  U Greinert; M Schlaak; S Rüsch-Gerdes; H D Flad; M Ernst
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

8.  Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model.

Authors:  M R Gyetko; G H Chen; R A McDonald; R Goodman; G B Huffnagle; C C Wilkinson; J A Fuller; G B Toews
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

9.  The changing pattern of nontuberculous mycobacterial disease.

Authors:  Joseph O Falkinham
Journal:  Can J Infect Dis       Date:  2003-09

Review 10.  Mycobacterium avium complex: advances in therapy.

Authors:  D V Havlir
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.